Advertisement

Abstract

Herpes zoster (HZ) is an acute segmental eruption of herpetiform-grouped vesicles due to endogenous reactivation of varicella-zoster virus (VZV) infection of nerval segments. Treatment of choice is systemic acyclovir and other antiviral agents are available. For elderly people, VZV vaccine is an option in secondary prevention.

Abbreviations

BW

Body weight

DNA pol

DNA polymerase

HZ

Herpes zoster

TK

Thymidine kinase

VZV

Varicella-zoster virus (VZV)

References

  1. Chen N, Yang M, He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2010;(12):CD005582.Google Scholar
  2. Ono F, Yasumoto S, Furumura M, Hamada T, Ishii N, Gyotoku T, et al. Comparison between famciclovir and valacyclovir for acute pain in adult Japanese immunocompetent patients with herpes zoster. J Dermatol. 2012;39(11):902–8.CrossRefGoogle Scholar
  3. Wassilew S, Collaborative Brivudin PHN Study Group. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol. 2005;19(1):47–55.CrossRefGoogle Scholar

Further Reading

  1. Baaros GAM, Miot HA, Massarico AM, Ramos F, Borges MA. Topical (S)-ketamine for pain management of postherpetic neuralgia. An Bras Dermatol. 2012;​87(3):504–6.CrossRefGoogle Scholar
  2. Cousins MJ, Pickthorn K, Huang S, Critchley L, Bell G. The safety and efficacy of KAI-1678 – an inhibitor of epsilon protein kinase C (εPKC) – versus lidocaine and placebo for the treatment of postherpetic neuralgia: A crossover study design. Pain Med. 2013. doi: 10.1111/pme.12058.CrossRefPubMedGoogle Scholar
  3. Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Brisson M, et al. Vaccination against herpes zoster in developed countries. State of the evidence. Hum Vaccin Immunother. 2013;9(5):1–8.CrossRefGoogle Scholar
  4. Gross G, Schöfer H, Wassilew S, Friese K, Timm A, Guthoff R, et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol. 2003;26(3):277–89.CrossRefGoogle Scholar
  5. Molina B, Gonzalez-Vicent M, Albi G, Herrero B, Sevilla J, Diaz MA. Varicella zoster central nervous system vasculitis after allogenic hematopoietic stem cell transplant successfully treated with cyclophosphamide. Transpl Infect Dis. 2012;14(5):E107–10.CrossRefGoogle Scholar
  6. Pentikis HS, Matson M, Atiee G, Boehlecke B, Hutchins JT, Patti JM, et al. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother. 2011;55(6):2847–54.CrossRefGoogle Scholar
  7. Schencking M, Vollbracht C, Weiss G, Lebert J, Biller A, Goyvaerts B, et al. Intravenous vitamin C in the treatment of shingles: results of a multicenter prospective cohort study. Med Sci Monit. 2012;18(4):​CR215–24.CrossRefGoogle Scholar
  8. Zerngast WW, Paauw DS, O’Connor KM. Varicella zoster with extended prodrome: a case series. Am J Med. 2013;126(4):359–61.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Dermatology and AllergologyAcademic Teaching Hospital Dresden-FriedrichstadtDresdenGermany

Personalised recommendations